Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study

摘要

Abstract Background Major depressive disorder (MDD) with concurrent anxiety symptoms may signal a difficult-to-treat patient. Brexpiprazole is a serotonin?￠????dopamine activity modulator: a partial agonist at 5-HT 1A and dopamine D 2 receptors at similar potency, and an antagonist at 5-HT 2A and noradrenaline alpha 1B/2C receptors. The objective of this Phase IIIb study was to explore effectiveness, safety, and tolerability of brexpiprazole adjunctive to antidepressant (ADT) monotherapy in patients with MDD and anxiety symptoms (NCT02013531). Methods Patients with MDD, Hamilton Anxiety Rating Scale (HAM-A) total score ?￠???￥ 20, and inadequate response to current ADT received open-label brexpiprazole 1?￠????3 mg day ?￠????1 (target dose 2 mg day ?￠????1 ) + ADT for 6 weeks. Efficacy endpoints included change from baseline at Week 6 in Montgomery?￠????????sberg Depression Rating Scale (MADRS) total score, HAM-A total score, and Sheehan Disability Scale (SDS). Safety and tolerability assessments included adverse events (AEs). Results Of 37 participants enrolled, 32 (86.5%) completed the study. Baseline mean ( SD ) MADRS total score was 30.1 (5.1); mean HAM-A total score was 26.9 (5.0). Improvements from baseline were observed at Week 6 for least squares mean change in MADRS total score (?￠????19.6, p < .0001 vs. baseline), HAM-A total score (?￠????17.8, p < .0001) and mean ( SD ) SDS mean score [?￠????3.6 (2.6)]. Brexpiprazole was well tolerated. The most frequent treatment-emergent AEs were increased appetite (13.5%) and diarrhea, dry mouth, and dizziness (all 10.8%). Conclusions These open-label results support the anxiolytic effects of adjunctive brexpiprazole in the treatment of patients with MDD.